Alcobra (ADHD) To Provide Corporate Overview At The Jefferies and Co. 2014 Global Healthcare Conference
5/27/2014 9:12:07 AM
TEL AVIV, Israel, May 27, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at the Jefferies 2014 Global Healthcare Conference taking place June 2-5 in New York City.
Help employers find you! Check out all the jobs and post your resume.
comments powered by